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In the article by Wright RS, Anderson JL, Adams CD, et al., “2011 ACCF/AHA Focused Update of the Guidelines for
the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007
Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on
Practice Guidelines,” which appeared in the May 10, 2011, issue of the Journal (J Am Coll Cardiol 2011;57:1920–59), the
ollowing corrections are necessary:
1. In Section 3.2.3.1.6, paragraph 5 (p. 1933), in the sentence beginning “The composite ischemic endpoint . . .,” p0.044
should be changed to p0.13. The complete sentence should read, “The composite ischemic endpoint occurred in 7.1%
of the patients assigned to upstream administration and in 7.9% of patients assigned to deferred selective administration
(RR: 1.12; 95% CI: 0.97 to 1.29; p0.13) (16), and thus the noninferiority hypothesis was not achieved.”
2. In Section 3.3 (p. 1933), wherein the reader is directed to Table 4 and Appendixes 3 and 6, it should be noted that
Appendix 8 also may be referenced. Thus, the sentence should be changed to “(See Table 4 and Appendixes 3, 6, and
8 for supplemental information.).”
3. In Table 5, Class I, column 2, recommendation #4 (p. 1936), the level of evidence should be changed from A to B, and
references 12 and 13 should also be cited. The complete recommendation should read as follows:
4. Clopidogrel 75 mg daily (preferred) or ticlopidine (in the absence of contraindications) should be given
to patients recovering from UA/NSTEMI when ASA is contraindicated or not tolerated because of
hypersensitivity or GI intolerance (despite use of gastroprotective agents such as PPIs) (11–13,61,108).
(Level of Evidence: B)
4. In Table 5, Class I, column 3 (p. 1936), the comment for recommendation #4 should be changed from “Modified
recommendation (changed wording for clarity)” to “Modified recommendation (changed wording for clarity; level of
evidence changed from A to B because trials do not address the specific subgroups in this recommendation).”
5. In Table 5, Class IIb, column 3 (p. 1936), the comment for recommendation #2 should be changed from “New
recommendation” to “New recommendation (to be concordant with 2009 STEMI and PCI Focused Update [32]).”
6. In Section 6.5.1, paragraph 4 (p. 1939), in the third sentence, “80 years” should be changed to “80 years.” The
complete sentence should read, “The SWEDEHEART (Swedish Web-System for Enhancement and Development of
Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies) study included a cohort of
23,262 patients hospitalized for NSTEMI in Sweden between 2003 and 2006 who were 80 years of age (161).”
7. In Section 6.5.1, paragraph 5 (p. 1939), in the last sentence, “with 1-year survival” should be changed to “with increased
1-year survival.” The complete sentence should read, “Early revascularization was associated with increased 1-year
survival in UA/NSTEMI patients with mild to moderate CKD, but no association was observed in those with severe
or end-stage kidney disease (161).”
8. In Appendix 4, column 4, Eptifibatide (p. 1946), in the first bullet, “30 mL/min” should be changed to “50
mL/min.” The complete sentence should read, “An LD of eptifibatide is FDA approved when the medication is initiated
in UA/NSTEMI patients who are started on medical therapy and when there is an appreciable delay to angiography/
PCI: LD of 180 mcg/kg IV bolus followed by MD of 2.0 mcg/kg per min started after bolus; reduce infusion by 50%
in patients with estimated creatinine clearance 50 mL/min (Class I, LOE: B).”
9. In Appendix 4, column 4, Prasugrel (p. 1946), the first bullet should be changed from “There is no clear need for
treatment with prasugrel before PCI” to “There are no data for treatment with prasugrel before PCI.”
10. In the Appendix 4 footnote, paragraph 2 (p. 1946), in the last sentence, “an approved dosage” should be changed to “an
approved or recommended dosage.” The complete sentence should read, “It is only meant to indicate an approved or
recommended dosage if a drug is chosen for a given situation.”
11. In Appendix 5, column 5, Loading dose (p. 1947), “60 mg” should be changed to “60 mg at time of PCI.”
12. In Appendix 5, column 3, Duration (p. 1947), “At least 1 y for DES” should be changed to “At least 1 y for BMS or
DES.”
13. In the Appendix 5 footnote (p. 1947), BMS should be added to the abbreviation note. The correct footnote should read,
“BMS indicates bare-metal stent; DES, drug-eluting stent; PCI, percutaneous coronary intervention; PPI, proton pump
inhibitor; TIA, transient ischemic attack; and UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction.”
14. In Appendix 6, tier 2 (p. 1948), the level of evidence for “Clopidogrel if ASA intolerant” should be changed from A to B.
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August 23, 2011:993–416. In the Appendix 6 footnote (p. 1948), the first sentence should be changed from “*If fondaparinux is used (Class I, LOE:
B) ...” to “*If fondaparinux is used with an invasive strategy (Class I, LOE: B), ... .” The complete sentence should read,
“*If fondaparinux is used with an invasive strategy (Class I, LOE: B), it must be coadministered with another
anticoagulant with Factor IIa activity, for example, unfractionated heparin.”
17. In Appendix 7, CURRENT-OASIS 7 (96), column 7, row 1 (p. 1949), “0.030 (0.83 to 1.06)” should be changed to
“0.30 (0.83 to 1.06).”
18. In Appendix 7, TIMACS (38), column 7, row 3 (p. 1950), “0.06 (0.48 to 0.89)” should be changed to “0.006 (0.48 to
0.89).”
19. In Appendix 7, EARLY-ACS (37), column 6, paragraph 1 (p. 1951), “... versus the delayed-eptifibatide group (10%)”
should be changed to “... versus the delayed-eptifibatide group (10%), but not significant.” The complete sentence should
read, “The primary endpoint was less in the early-eptifibatide group (9.3%) versus the delayed-eptifibatide group (10%),
but not significant.”
20. In Appendix 7, EARLY-ACS (37), column 6, paragraph 3 (p. 1951), “(... delayed-eptifibatide group; p0.001), less
severe GUSTO bleeding” should be changed to “(... delayed-eptifibatide group; p0.001), similar severe GUSTO bleeding.”
The complete sentence should read, “Patients in the early-eptifibatide group experienced higher TIMI major hemorrhage
compared with the delayed-eptifibatide group (2.6% versus 1.8%, respectively), higher rates of moderate GUSTO bleeding
(6.8% in the early-eptifibatide group versus 4.3% in the delayed-eptifibatide group; p0.001), similar severe GUSTO bleeding
(0.8% early-eptifibatide group versus 0.9% in delayed-eptifibatide group; p0.97), and need for red-cell transfusion was
increased in the early-eptifibatide group compared with the delayed-eptifibatide group (8.6% versus 6.7%, respectively;
p0.001).”
1. In Appendix 7, EARLY-ACS (37), column 7, row 3 (p. 1951), “0.02” should be changed to “0.02 (1.07 to 1.89).”
2. In Appendix 7, EARLY-ACS (37), column 8, row 3 (p. 1951), “OR: 1.42; 95% CI: 1.07 to 1.89” should be changed
to “OR: 1.42.”
3. In Appendix 7, ABOARD (120), column 6, paragraph 1 (p. 1952), “(median 2.1 versus 1.7 mg/mL” should be changed
to “(median 2.1 ng/mL [0.3 to 7.1 ng/mL] versus 1.7 ng/mL [0.3 to 7.2 ng/mL].” The complete sentence should read,
“No difference was found in peak troponin-I between groups (median 2.1 ng/mL [0.3 to 7.1 ng/mL] versus 1.7 ng/mL
[0.3 to 7.2 ng/mL] in immediate- and delayed-intervention groups, respectively).”
4. In Appendix 7, ABOARD (120), column 6, paragraph 2 (p. 1952), in the first sentence, “and 10.2%” should be changed
to “versus 10.2%.” The complete sentence should read, “Secondary endpoint was seen in 13.7% (95% CI: 8.6% to 18.8%)
of immediate-intervention group versus 10.2% (95% CI: 5.7% to 14.6%) of delayed-intervention group.”
5. In Appendix 7, ABOARD (120), column 7, row 1 (p. 1952), “0.79” should be changed to “0.70 (N/A).”
6. In Appendix 7, ABOARD (120), column 8, row 1 (p. 1952), the OR/HR/RR value is blank and should be changed to
“(N/A).”
7. In Appendix 7, ABOARD (120), column 8, row 2 (p. 1952), the OR/HR/RR value is blank and should be changed to
“(N/A).”
8. In Appendix 7, TRITON-TIMI 38 (22), column 6, paragraph 2 (p. 1952), “similar” should be changed to “consistent.”
The complete sentence should read, “Primary endpoint was consistent in UA/NSTEMI cohort (9.9% with prasugrel
versus 12.1% with clopidogrel; 18% RR).”
9. In Appendix 7, TRITON-TIMI 38 (22), column 6, paragraph 5 (p. 1952), “Efficacy benefit from Day 3” should be changed
to “Efficacy benefit evident from Day 3.” The complete sentence should read, “Efficacy benefit evident from Day 3 to end of
follow-up (5.6% in patients receiving prasugrel versus 6.9% of patients receiving clopidogrel).”
0. In Appendix 7, TRITON-TIMI 38 (22), column 7, row 8 (p. 1952), the p (95% CI) value is blank and should be
changed to “0.01 (1.08 to 2.13).”
1. In Appendix 7, TRITON-TIMI 38 (22), column 8, row 8 (p. 1952), the OR/HR/RR value is blank and should be
changed to “HR: 1.52.”
2. In Appendix 7, SWEDEHEART (161), column 7, row 4 (p. 1953), “0.001 (0.51 to 1.61)” should be changed to “0.001
(0.54 to 0.81).”
3. In Appendix 7, SWEDEHEART (161), column 8, row 4 (p. 1953), “HR: 0.91” should be changed to “HR: 0.68.”
4. In Appendix 7, SWEDEHEART (161), column 7, row 5 (p. 1953), “0.940 (0.51 to 1.61)” should be changed to “0.740
(0.51 to 1.61).”
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